1- Lance JW. Symposium Synopsis. In: Infeldman RG, Young RR, Koella WP. Spasticity:Disordered Motor
Control. Chicago: Year Book Medical Publishers; 1980.
2- Nathaniel H, Mayer. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper
motor neuron lesion. Muscle & nerve 1997; 6(Supple.): 1-11.
3- Elovic EP, Simone KL, Zafonte R. Outcome assessment for spasticity management in the patients with traumatic
brain injury. Head trauma Rehabil, 2004; 19(2): 155-77.
4- Bobath B. Adult hemiplegia, evaluation and treatment. 2nd Edition.London: William Heinemann Medical book
5- Mitchell f Brin. Botulinum toxin: chemistry, pharmacology, Tixicity and Immunology. Muscle & nerve, 1997;
6- Aoki KR. Pharmacology and immunology of BTX-A. clin Dermatol. 2003; 21(6): 476-80.
7- Bhidayasiri R, Troung OD. Expanding use of botulinum toxin. J Neurol Sci 2005; (1-2):1-9.
8- Raymond A, Arimura K, Trakenaga S. Extrafusal and intrafusal muscle effects in experimental BTX-A
injections. Muscle & Nerve 1996; 19: 488-96.
9- Yagiz on A, Kirazli Y, Kismali B. Mechanisms of action of phenol block and BTX-A in relieving spasticity
.Muscle & Nerve 1999; 78(4): 344-49.
10- Stampacchia G, Bradaschia E. Change of stretch reflex threshold in spasticity: Effect of BTX- A injections.
Arch Ital Biol 2004; 142(3): 263-73.
11- Albany K. Physical and occupational theraphy considerations in adult patients receiving botulinum toxin
injections for spasticity. Muscle & Nerve 1997; Supplement 6: 221-229.
12- Bohannon R, Smith MB. Interrater reliability of a modified ashworth scale of muscle spasticity. Physiotherapy
13- Kimura J. Electrodiagnosis in disease of nerve and muscle, Principles and practice. 2nd edition. F.A Davis
Company; 1989. 356-368.
14- Brin F. Dosing administration and atreatment algorithm for use of BTX-A for adult-onset spasticity. Muscle &
nerve 1997; 6(Suppl.): 206-220.
15- Funase K, Higashi T, Yoshimura. Evident difference in the excitability of the motoneuron pool between normal
subjects and patients with spasticity assessed by a new method using H- reflex and M –response. Neuroscience
Letters 1996; 203:127-130.
16- Lefaucheur JP. Electrophysiological Assessment of reflex pathway involved in spasticity. Neurochirugie 2003;
17- Pauri F, Boffa L, Cassette E. Btx-A treatment in spastic paraparesis: a neurophysiological study. J Neurol Sci
2000; 181: 89-97.
18- Koman LA, Mooney JF, Smith BP. Neuromuscular Blockage in the treatment of lower extremity spasticity in
cerebral palsy. J pediatr Orthop 2000; 20(1): 108-15.
19- Richardson D, Sheen G, Werring D. Evaluating the role of botulinum toxin in the management of focal
hypertoniain adults. J Neurol Neurosurg Psychiatry 2000; 69(4): 499-506.
20- Lagalla G, Danni M, Reiter F. Post stroke spasticity management with repeated botulinum toxin injections in the
upper limb. Am J Phys Med Rehabil 2000; 79 (4): 377- 84.
21- Gormely Jr, Obrein F, Yablin S. A clinical overview of treatment decision in the management of spasticity.
Muscle & nerve 1997; 6(suppl.):14-30.
22- Graham HK , Aoki KR, Autti I, Boyd RN, Delgado MR, Gormley ME. Recommendations for the use of
botulinum toxin type A in the management of cerebral palsy. Gait and Posture 2000; 1: 67-79.
23- Leach J. hildren undergoing treatment with botulinum toxin: The role of the physical therapist. Muscle & Nerve
1997; Supplement 6: 194-204.
24- Suputtitada A. Managing spasticity in pediatric cerebral palsy using a very low dose of botulinum toxin type A.
Am-J-Phys-Med-Rehabil 2000; 79(2):11-14.
25- Lim EC, Ong BK, Seet RC. Botulinum toxin – A injections for spastic toe clawing .Parkinsonism related Disord
26- Pidcock FS. The emerging role of therapeutic BTX-A in the treatment of cerebral palsy. J pediatr 2004; 145 (2
27- Russman BS, Tilton A, Gormley M. Cerbral palsy: A rational approach to a treatment protocol, and the role of
botulinum toxin in treatment. Muscle & Nerve 1997; Supplement 6: 181-190.